The Optimal Timing of Ambu® AuraOnce™ Laryngeal Mask Airway Insertion with Propofol Induction

Wei Chen¹, Rebecca Downey¹, Richard Sheu¹,², Hui Qu³, Iwona Bonney¹ and Peishan Zhao¹*

¹Department of Anesthesiology and Perioperative Medicine, Tufts Medical Center, USA
²Department of Anesthesiology and Pain Medicine, University of Washington Medical Center, USA
³Department of Epidemiology and Public Health, School of Public Health, Yale University, USA

Abstract

Background: Laryngeal Mask Airway (LMA) is usually inserted without muscle relaxants, which requires good jaw relaxation. Previous studies have focused on creating the optimal condition for LMA insertion with different anesthetic adjuncts. This study is to determine whether the time interval between induction and insertion influences placement conditions.

Methods: This is a prospective randomized study with a total of 198 ASA I or II patients assigned to three groups: Group 0", Group 60" and Group 90", with number representing the seconds from loss of Eye Lash Reflex (ELR) to LMA insertion. All patients were pretreated with intravenous midazolam 2 mg and fentanyl 1 mcg/kg at a given time. Induction was achieved with 2.5 mg/kg propofol. Ambu® AuraOnce™ LMA was placed by a blinded anesthesiologist who also assessed the condition for LMA insertion based on a score system. The primary outcome is to find the optimal condition for LMA insertion in each group. The conditions were defined as optimal or non-optimal based on the total score of 6 or >6, respectively.

Results: The percentage of the optimal condition was significantly different amongst the three groups (p=0.031). The optimal condition was 68% in Group 60", that was significantly higher than 45% in Group 0" (p=0.008), but not than 58% in Group 90" (p=0.207).

Conclusion: Induction of general anesthesia with 2.5 mg/kg of propofol, with pre-administration of midazolam and fentanyl, provided the highest percentage of optimal condition of LMA insertion at 60 sec after loss of ELR.

Keywords: Laryngeal Mask Airway (LMA); Optimal timing; Propofol; Laryngospasm; General anesthesia

Introduction

Since its prototype introduction in 1983, Laryngeal Mask Airway (LMA) has been used worldwide for General Anesthesia (GA) in properly selected patients, as an alternative to the Endotracheal Tube (ETT). By 2011, an estimated 56% of GA was managed by some form of supraglottic airway in the United Kingdom [1]. Compared to ETT, the use of LMA results in lower incidence of laryngospasm, postoperative hoarse voice, and coughing [2]. Similar to ETT placement, the insertion of LMA requires a certain depth of anesthesia to achieve adequate jaw-opening and to avoid undesirable events. These undesirable events include coughing, gagging, patient movements, and laryngospasm. Prior studies have focused primarily on the comparisons of various anesthetic agents and anesthetic adjuncts to create an optimally induced patient to aid easy insertion of LMA. Several anesthetic adjuncts such as midazolam [3], opioids [4,5], lidocaine [6], and ketamine [7] have shown to reduce the dose of propofol and create satisfactory LMA insertion conditions. LMA placement conditions were also enhanced with muscle relaxants [8,9]. However, the time frames at which the LMAs were inserted after induction in all of these studies were either subjective (determined by the inserter) or inconsistent, thus making it unclear whether the time interval between induction and insertion influences placement conditions.

This pilot study sought to investigate the optimal timing of Ambu’ AuraOnce™ LMA (Ambu Inc. Glen Burnie, MD, USA) insertion with the most commonly used IV anesthetic induction agent, propofol, without co-administration of muscle relaxant. The 0 sec, 60 sec, and 90 sec were chosen as the intervals in the study, because the argument about the timing of LMA placement usually falls...
immediately after or sometime after the induction. We hypothesized that immediate placement after propofol induction, defined by loss of Eye Lash Reflex (LER), would provide the best LMA insertion conditions based on empirical experience.

**Material and Methods**

This study was approved by the Institutional Review Board (IRB) at Tufts Medical Center (TMC), and written informed consent was obtained from all subjects. The trial was registered at clinicaltrials.gov before patient enrolment (NCT 00972491, Principal investigator: Peishan Zhao, date of registration: September 7th, 2009) and this manuscript followed the applicable Equator guidelines.

**Sample size estimation**

With limited literature on the research topic of this study, the sample size calculation was based on a study by Wong et al. [10] that showed a 65% rate of “optimal condition” following induction of subjects at 90 sec. For the purpose of our power and sample size estimation, we took this 65% rate to be true for 60 sec as well. To achieve 90% power to detect a linear trend in the optimal condition of LMA insertion, while using a two-sided Chi-squared test for trends and a significant p-value of 0.05, a sample size of 66 per group was needed. The simple size estimation and patient randomization scheme were generated by statistician in the research institute at TMC.

**Patient selection and randomization**

Between October 2009 and December 2013, 250 eligible subjects were selected to be recruited to make sure the sample size was met for proper analysis. Regardless of gender or ethnicity, patients 18 years or older with an American Society of Anesthesiologists (ASA) physical status I-II and scheduled to undergo a surgical procedure at TMC for which LMA was an appropriate choice were recruited. Exclusion criteria included: patients with risk of aspiration; mouth opening <2.5 cm; limitation of neck movement; anticipated difficult airway; obstructive sleep apnea; morbid obese patients defined as Body Mass Index (BMI) ≥ 40 or 35 with one serious obesity-related condition; pregnant women; prisoners; use of sedative or recreational drugs; patient refusal, known allergic reaction to the drugs used and operative procedure for which use of an LMA was not deemed safe.

After informed consents were obtained, the enrolled subjects were randomly assigned to one of the three study groups: Group 1: 0 sec, Group 2: 60 sec, and Group 3: 90 sec, which respectively represented the time-lapse in seconds after loss of ELLR. The randomization scheme was developed using SAS 9.1.3 (SAS Institute Inc., Cary, NC). Randomization envelopes were opened only when the subject agreed to participate in the study.

**Study protocol**

A peripheral Intravenous (IV) line and infusion of lactated ringer’s solution were started in the holding area prior to surgery. In addition, routine 2 mg of IV midazolam was given to all participants’ right before being taken to the OR. Upon arrival to the OR, IV fentanyl 1.0 mcg/kg was given before standard ASA monitors were placed. Vital signs were taken as a pre-induction baseline and then taken immediately 1 min, 2 min and 3 min after LMA insertion. Participants were preoxygenated for 3 min and pre-treated with 2 ml of 2% lidocaine IV to decrease pain upon injection [11]. Induction was performed immediately after lidocaine injection by investigator 1 with IV propofol 2.5 mg/kg injected over a 15 sec span and was concluded after loss of LER determined by investigator 1. After investigator 1 tracked 0 sec, 60 sec, or 90 sec of time-lapsed, a blinded investigator 2 (LMA inserter) was summoned to insert size 4 LMAs for females and size 5 for males. Investigator 2 was present in the OR and blinded to randomized groups by facing the OR wall opposite to the OR table. The LMAs were lubricated with a water soluble gel and inserted with a deflated cuff according to the technique described by Brain [12]. The cuff was then inflated with 20 mL to 30 mL of air. The correct position of the LMA was confirmed by observing adequate chest rise, auscultating leakage in the neck, observing the capnogram and tidal volume, and absence of audible air leak. After LMA placement, anesthesia management was transferred to the primary team. Five attending anesthesiologists acted as investigator 2 and were trained by the primary investigator prior to the study regarding the score system used. The LMA insertion condition was graded by investigator 2 based on 6 categories used in previous studies [10,13]. The primary outcome was the optimal condition defined as a total score of 6 (see below) in each group. Non-optimal condition was based on a total score >6. Secondary outcomes include: jaw opening (full 1, partial 2, and nil 3); insertion of LMA (easy 1, difficult 2, and impossible 3); coughing or gagging (none 1, some 2, and significant 3); hiccups (none 1, some 2); head or body movement (none 1, some 2, and significant 3) and laryngospasm or airway obstruction (none 1, partial 2, total 3). Laryngospasm is defined as airway obstruction with assumption that LMA is correctly placed. The numbers represent scores.

The apneic patient was mask ventilated with 100% oxygen only if O2 saturation decreased to less than 92% between loss of LER and LMA placement. If the LMA insertion was not successful on the first attempt, another dose of propofol 1 mg/kg was given with a second attempt 30 sec later. If the second attempt was unsuccessful, propofol 0.5 mg/kg was administered and a third attempt was performed 30 sec later. If the third attempt was unsuccessful, ETT intubation was initiated.

**Statistical analysis**

Continuous variables were summarized as mean ± standard deviation, and categorical variables were summarized as frequency and percentages. The dependent variable/primary outcome (optimal conditions) and the independent variable (time of LMA insertion) represent ordinal variables with logical ordering i.e. (yes, no) and (0, 60 and 90 sec). These variables were tested with a chi-squared test for association. Other categorical outcomes such as jaw opening ease of LMA insertion, presence of coughing/gagging/hiccups, head and body movement, and occurrence of laryngospasm or airway obstruction, were analyzed in the same way. We used ANOVA to test the relationship between randomized groups and hemodynamic responses to LMA insertion (continuous variables). When data was skewed (number of attempts, total score, O2 saturation at baseline, before and after insertion), we used a non-parametric test for association. When there were significant differences among groups, we used a t-test to show differences between each of the two groups. All data was analyzed using SAS 9.4 (SAS Institute Inc., Cary, NC). Statistical analysis was performed using SPSS (version 13.0; SPSS Inc., Chicago, IL, USA). The level of significance was set at a p value <0.05.

**Results**

We planned to recruit 250 subjects to make sure we had 66 subjects in each group. In reality, we approached 236 subjects after meeting the goal of 198 subjects in total for statistical analysis. There
were no significant differences between groups regarding age, gender, height, weight, BMI, ASA physical status, history of asthma or drinking/smoking.

We found that Group 2 had the highest percentage of optimal condition for LMA insertion at 68%, followed by 58% in Group 3. The least percentage of optimal condition was 45% in Group 1. Although there were no significant differences in the individual score amongst the three groups, there was significant difference in the number of optimal conditions (score = 6) amongst these groups (p=0.031). The percentage of optimal conditions was significantly higher in Group 2, compared with Group 1 (p=0.008). However, there was no significant difference of number of optimal conditions between Group 1 and Group 3 (p=0.164) or Group 2 and Group 3 (p=0.207). The greatest contribution of this difference came from jaw opening where 80.3% in Group 2 were able to have full jaw opening, which was significantly higher than 65.2% in Group 1 (p=0.051).

Multivariable ordered logistic regression models were developed and used to scan for potential confounding variables. Adjustments were made to age, height, weight, BMI, history of asthma, smoking and drinking status, ASA physical status and time to insertion in the full model. Using a backward selection procedure, findings that only “time to insertion” was significant (p=0.0328), so it remained in the reduced model. It showed that compared to Group 1, the odds of getting an optimal condition was 2.57 times significantly higher in Group 2 [95% CI (1.265 to 5.226)], and 1.62 times higher in Group 3 [95% CI (0.819 to 3.236)].

There was no difference in pre-induction systolic and diastolic Blood Pressures (BP) and Heart Rate (HR) amongst the three groups. However, the immediate post-insertion systolic BP of Group 1 was significantly higher than that of Group 2 (p=0.0004) and Group 3 (p=0.0014). In addition, the immediate post-insertion HR of Group 1 was significantly higher than that of Group 2 (p=0.028) and Group 3 (p=0.0184). When compared, the hemodynamic changes between 1 min post LMA insertion and pre-induction showed that there were no significant changes in HR and systolic BP amongst the three groups. In regard to diastolic BP changes, that of Group 1 was not significantly higher than that of Group 2 (p=0.054) but was significantly higher than that of Group 3 (p=0.021). There were 7 patients in Group 1, 5 patients in Group 2 and 2 patients in Group 3 that required second attempts to place LMA. However, no patients required intubation throughout the entirety of the study.

**Discussion**

Propofol has rapid onset of action with a peak effect of 1.6 min and a decline of effects within minutes due to redistribution from Central Nervous System (CNS) to muscles and adipose tissues [14]. Moreover, propofol possesses muscle relaxing properties with central mechanisms [15]. The onset time of muscle relaxation is 10 sec to 20 sec, with effect lasts 4 min to 6 min [16]. IV propofol induction has been shown to be superior to thiopental due to its lower incidence of postoperative complications [8,17]. These properties make propofol a popular induction agent for GA with LMA. A 2.5 mg/kg dose was recommended for IV bolus induction of GA [18]. However, when 2.5 mg/kg propofol is used alone in un-premedicated patients it may provide less satisfactory conditions of LMA insertion, giving rise to patient gagging, coughing, body movement and even laryngospasm [19]. We co-administered 1 mcg/kg fentanyl with 2.5 mg/kg propofol because this dose, in a previous study, provided optimal conditions for LMA insertion in most studied subjects (65% of cases) [10]. Lower dose (0.5 mcg/kg) of fentanyl or placebo had higher incidence of unsatisfied mouth opening and LMA insertion, more swallowing and patient movement, while higher doses (1.5 and 2.0 mcg/kg) of fentanyl resulted in higher incidence of coughing/gagging and laryngospasm [10]. In addition, 1 mcg/kg fentanyl provided similar conditions for LMA insertion and better hemodynamic parameters than 2 mcg/kg fentanyl [20]. We injected fentanyl when the patient was brought to the OR because the time from entering OR to induction of GA was approximately 5 min, which is the optimal onset time of fentanyl before tracheal intubation [21]. During the study period, we routinely gave each patient midazolam as an anxiolytic before transferring to OR.

Contrary to our hypothesis, we found that the best time to insert LMA is 60 sec after loss of ELR, since 68% patients had the optimal condition for LMA insertion at this time point. Compared with 0 sec, the odds ratio of optimal condition is 2.57 at 60 sec and 1.62 at 90 sec. No study was found comparing time-lapse between induction and LMA insertion. Previous studies that focused on the insertion condition and complications of LMA placement used 0 sec 3 min intervals from propofol induction to insertion of LMA [20,22]. However, in a dose response study to determine an optimal dosage of fentanyl used with propofol for LMA insertion, Wong et al. [10] pre-administered fentanyl 1 mcg/kg (injected over 10 sec) followed immediately by 2.5 mg/kg propofol (injected over 10 sec) as an induction agent and achieved optimal condition for LMA insertion in 65% of subjects. The author’s inserted LMA 90 sec after patient received the first medication, fentanyl. Considering patient loss of ELR within 10 sec after propofol injection [13], we calculated insertion time in Wong’s study that is very close to 60 sec after patient loss of ELR. Bapat et al. [6] compared condition for LMA insertion after induction with 1 mcg/kg Fentanyl, followed 60 sec later by 2.5 mg/kg propofol (Group P), or 1.5 mg/kg lidocaine followed 30 sec later by 5 mg/kg thiopentone (Group LT), or 0.1 mg/kg midazolam followed 3 min later by 5 mg/kg thiopentone (Group MT). LMA was inserted 60 sec after induction. They found 66% (33/50) of patients in propofol group had excellent conditions for LMA insertion. In addition, there was no laryngospasm in propofol group compared to 28% and 6% in LT group and MT group, respectively. No midazolam was given to the patients in these 2 comparable studies. In this study, 2 mg of IV midazolam (average 0.03 mg/kg) was given to all patients. Midazolam at 0.04 mg/kg reduced the propofol induction dose of GA for LMA insertion [3], which might explain the better result we found. It should be noticed that induction with only 2.5 mg/kg propofol does not seem to provide an optimal condition for LMA insertion at 60 sec after loss of ELR. When compared to induction with 8% sevoflurane in 50% nitrous oxide and oxygen, induction with 2.5 mg/kg propofol without pre induction opioids or benzodiazepines led to 11% (5/44) laryngospasm and higher incidences of coughing, gagging and body movement [23].

LMA is usually placed without muscle relaxants. Full jaw opening shows reduced muscular tone and increased success rate of LMA insertion. Limited jaw opening is acknowledged as a cause of difficult placement of LMA. Ganatra et al. [13] used maximum jaw relaxation as the time point to insert LMA. They used fentanyl 1 mcg/kg followed 3 min later with 2.5 mg/kg propofol injected over 45 sec. The mean time taken from induction to successful LMA insertion was 73 sec. We injected propofol over 15 sec and had the most optimal jaw opening condition at 60 sec (80.3%). The total time from start of
induction to LMA insertion was 75 sec, which is very close to the 73 sec in Ganatra’s study. The maximum muscle relaxing property of propofol seemed to be well correlated with its peak effect at 1.6 min.

Early studies indicated that in adults, the incidence of laryngospasm was 1% to 4% during LMA placement [24]. One patient in study Group 1 had a laryngospasm. This patient was a 41 year old otherwise healthy non-obese female who presented for excision of excision of left breast mass. She had no history of tobacco or chronic alcohol use. After LMA insertion, the patient had typical inspiratory stridor, then paradoxical respiratory effort and tracheal tug, but no end tidal CO₂ was seen on the monitor. The laryngospasm was broken by injection of more propofol, removing of LMA and positive pressure ventilation.

Among the risk factors for laryngospasm during anesthesia [25], we found the only possible provoker of laryngospasm in our patient was light level of anesthesia. In comparison to pre-induction vital signs, the systolic BP and HR of Group 1 immediately after post-insertion, maintained significantly better than that of Group 2 and Group 3. This may suggest depth of anesthesia in Group 1 was not as deep as the other 2 groups. Our result clearly indicated that the time of 0 sec was not the best time to place LMA. Previous studies also indicated that in most instances, the conditions were less than optimal when insertion of LMA was attempted immediately after the loss of verbal contact [26].

Anesthesia providers usually place LMA even without optimal condition. In our study, 32% to 55% of patients did not have an optimal condition for insertion. Only 3% (2/66 in Group 3) to 11% (7/66 in Group 1) had LMA inserted with second attempt. Similarly, 7% to 20% of patients required more than one attempt for LMA insertion in Wong’s study although less than 65% subjects had optimal conditions [10]. With current advances in medication such as propofol and anesthesia providers’ techniques, laryngospasms during LMA insertion does not happen as often as it used to [24,27]. However, to avoid potential complications, one should wait for the optimal condition achieved before LMA insertion, especially in current busy practice.

Coughing and gagging occurred in 2 patients in Group 1 and 1 patient in Group 3, but none in Group 2, which is consistent with the overall result those 60 sec, is the best time to insert LMA. Body/head movement occurred in some patients in each group with similar incidence. The dose of propofol required to produce loss of motor response to jaw thrusting varies considerably (95% reference interval: 1.7 mg/kg to 3.6 mg/kg) [26]. This wide variability implies that a fixed dose of propofol, 2.5 mg/kg may be more than needed for some patients, while not enough for others. The wide inter-individual variability may be the reason why similar numbers of patients in each group had movement.

Propofol is known to cause hiccups [28,29]. The incidence of propofol hiccups is unknown. Hiccups occurred in 1 patient in Group 1 and 2 patients in Group 2 and Group 3 each. Hiccups spontaneously resolved in each of the patients. However, hiccups could result in laryngospasm [29] and more attention should be paid to patient with this side effect. Lidocaine 1 mg/kg IV was successfully used to relieve hiccups [29].

Propofol inhibits the activity of peripheral sympathetic nervous system, leading to a decrease in peripheral vascular resistance and low blood pressure [30]. Compared to pre-induction BP, our patient’s systolic and diastolic BP dropped 8 mmHg to 19 mmHg and 5 mmHg to 10 mmHg respectively, immediate after LMA insertion, and 14 mmHg to 20 mmHg and 8 mmHg to 13 mmHg respectively, 1 min post insertion. This decrease in BP is within 20% of pre-induction values that is an acceptable change under GA. However, patients with cardiac comorbidities may not tolerate this BP change. In contrast, the HR of patients was stable during induction and LMA insertion, which is consistent with previous studies [20,31]. Heart Rate Variability (HRV) is controlled by the central nervous system. Propofol may have differential effects on the peripheral and cardiac autonomic nervous systems. Propofol inhibits the cardiac parasympathetic nerve to a greater degree than the sympathetic nerve [31]. However, the direct negative chronotropic effect of propofol [32] may offset an increase in HR response. This may explain the stability of HR after propofol injection in our study.

This is a prospective, double-blind, randomized controlled study. However, there were several limitations noticed during the study. First, time intervals of 30 sec, 45 sec, 120 sec, etc., were not included due to the nature of a pilot study. The time points within 120 sec is worthy of further study, since most anesthesia providers do not wait 2 min after disappearance of ELR to insert LMA. Secondly, previous study showed that males were more sensitive to propofol [33] and sensitivity to propofol also increased with age [34]. However, patients' demographics were evenly distributed in the three groups. We do not believe that this gender and age difference in propofol pharmacology affected the outcome of our study. Thirdly, to make sure the accurate insertion time occurred, the LMA inserter (anesthesiologist 2) needed to be present in the OR. Although one may argue that this anesthesiologist may not be totally blind by guessing the study time point, we asked LMA inserter not to look at the induction of GA and inducing anesthesiologist kept talking to the patient even in sleep.

Conclusion

In conclusion, under our study condition, we found that the best time to insert Ambu AuraOnce™ LMA was 60 sec after loss of ELR, since 68% patients had the optimal condition for LMA insertion at this time point. The odd ratio of optimal condition is 2.6 at 60 sec and 1.6 at 90 sec compared to 0 sec.

References

1. Van Zundert TC, Bramcombe JR, Ferson DZ, Bacon DR, Wilkinson DJ. Archie Brain: Celebrating 30 years of development in laryngeal mask airways. Anaesthesia. 2012;67(12):1375-85.
2. Yu SH, Beirne OR. Laryngeal mask airways have a lower risk of airway complications compared with endotracheal intubation: A systematic review. J Oral Maxillofac Surg. 2010;68(10):2359-76.
3. Gill PS, Shah J, Ogilvy A. Midazolam reduces the dose of propofol required for induction of anaesthesia and laryngeal mask airway insertion. Eur J Anaesthesiol. 2001;18(3):166-70.
4. Hui JK, Critchley LA, Karmakar MK, Lam PK. Co-administration of alfentanil-propofol improves laryngeal mask airway insertion compared to fentanyl-propofol. Can J Anaesth. 2002;49(5):508-12.
5. Bouvet L, Da-Col X, Rimmelt T, Allouchiche B, Chassard D, Boselli E. Optimal remifentanil dose for laryngeal mask airway insertion when co-administered with a single standard dose of propofol. Can J Anaesth. 2010;57(3):222-9.
6. Bapat P, Joshi RN, Young E, Jago RH. Comparison of propofol versus thiopentone with midazolam or lidocaine to facilitate laryngeal mask insertion. Can J Anaesth. 1996;43(6):564-8.
7. Goh PK, Chiu CL, Wang CY, Chan YK, Loo PL. Randomized double-blind comparison of ketamine-propofol, fentanyl-propofol and propofol-
saline on haemodynamics and laryngeal mask airway insertion conditions. Anaesth Intensive Care. 2005;33(2):223-8.
8. Eftekhar J, Kazemi Hakibi, Tizro P, Alizadeh V. A comparison to facilitate insertion of the laryngeal mask: Term of recovery and postoperative nausea and vomiting after anesthesia with propofol- atracurium and thiopental-atracurium. Acta Med Iran. 2015;53(2):117-21.
9. Koh KF, Chen FG, Cheong KF, Esvaranathan V. Laryngeal mask insertion using thiopental and low dose atracurium: A comparison with propofol. Can J Anaesth. 1999;46(7):670-4.
10. Wong CM, Critchley LA, Lee A, Khaw KS, Ngan Kee WD. Fentanyl dose-response curves when inserting the LMA classic laryngeal mask airway. Anaesthesia. 2007;62(7):654-60.
11. Johnson RA, Harper NJ, Chadwick S, Vohra A. Pain on injection of propofol methods of alleviation. Anaesthesia. 1990;45(6):439-42.
12. Brain AL, McGhee TD, McAteer EJ, Thomas A, Abu-Saad MA, Bushman JA. The laryngeal mask airway. Development and preliminary trials of a new type of airway. Anaesthesia. 1985;40(4):356-61.
13. Ganatra SB, D’Mello J, Butani M, Jhamnani P. Conditions for insertion of the laryngeal mask airway: Comparisons between sevoflurane and propofol using fentanyl as a co-induction agent. A pilot study. Eur J Anaesthesiol. 2002;19(5):371-5.
14. Struys MM, De Smet T, Depoorter B, Verschelen LF, Mortier EP, Dumortier FJ, et al. Comparison of plasma compartment versus two methods for effect compartment--controlled target-controlled infusion for propofol. Anesthesiology. 2000;92(2):399-406.
15. Dueck MH, Oberthuer A, Wedekind C, Paul M, Boerner U. Propofol impairs the central but not the peripheral part of the motor system. Anesth Analg. 2002;94(2):449-55.
16. Borgeat A, Dessibourg C, Rochani M, Suter PM, et al. Propofol or sevoflurane for laryngeal mask airway insertion. Can J Anaesth. 1999;46(4):322-6.
17. Asai T, Morris S. The laryngeal mask airway: Its features, effects and role. Can J Anaesth. 1994;41(10):930-60.
18. Gavel G, Walker RWM. Laryngospasm in anesthesia. Contin Educ Anaesth Crit Care Pain. 2014;14(2):47-51.
19. Durance MP, Nunez J, Vaughan RS, Asai T. Jaw thrusting as a clinical test to assess the adequate depth of anaesthesia for insertion of the laryngeal mask. Anaesthesia. 1996;51(12):1167-70.
20. Olsson GL, Hallen B. Laryngospasm during anesthesia. A computer-aided incidence study in 136 929 patients. Acta Anaesth Scand. 1984;28(5):567-75.
21. Khan K. Muscle twitching and hiccups with propofol. J Anaesthesiol Clin Pharmacol. 2011;27(3):418.
22. Landsers C, Turner D, Makin C, Zaglul H, Brown R. Propofol associated hiccups and treatment with lidocaine. Anesth Analg. 2008;107(5):1757-8.
23. Robinson BJ, Ebert TJ, O’Brien TJ, Colin MD, Muzi M. Mechanisms whereby propofol mediates peripheral vasodilation in humans: Sympathetic inhibition or direct vascular relaxation? Anesthesiology. 1997;86(1):64-72.
24. Kanaya N, Hirata K, Kurosawa S, Nakayama M, Namiki A. Differential effects of propofol and sevoflurane on heart rate variability. Anesthesiology. 2003;98(1):34-40.
25. Yamamoto S, Kawana S, Miyamoto A, Ohshika H, Namiki A. Propofol induced depression of cultured rat ventricular myocytes is related to the M2-acetylcholine receptor -NO-cGMP signaling pathway. Anesthesiology. 1999;91(6):1712-9.
26. Schneider TW, Minto CF, Shaffer SL, Gambus PL, Andresen C, Goodale DB, et al. Influence of age on propofol pharmacodynamics. Anesthesiology. 1999;90(6):1502-16.